Tempest receives orphan drug designation from the u.s. food and drug administration for amezalpat to treat patients with hepatocellular carcinoma (hcc)

Brisbane, calif., jan. 06, 2025 (globe newswire) -- tempest therapeutics, inc. (nasdaq: tpst), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the u.s. food and drug administration (fda) has granted orphan drug designation (odd) to amezalpat (tpst-1120), an oral, small molecule, selective ppar⍺ antagonist for the treatment of patients with hepatocellular carcinoma (hcc).
HCC Ratings Summary
HCC Quant Ranking